InstalabComprehensive ANA Panel
Should you take a Comprehensive ANA Panel test?
This test is most useful if any of these apply to you.
12 biomarkers included
- ANA ScreenThe broad first pass that detects antinuclear antibodies, immune proteins aimed at your own cell nuclei; highly sensitive, so true disease is rarely missed.Why it mattersA positive screen opens the investigation but proves nothing by itself; the specific antibodies decide what it means.
- ANA TiterMeasures how strong the signal is by how far your blood can be diluted and still test positive; higher titers carry more weight.Why it mattersA titer of 1:320 or higher strongly favors real autoimmune disease, while low titers are common in healthy people.
- ANA PatternDescribes the shape the antibodies make when they light up cells under a microscope, pointing toward which specific antibodies to test next.Why it mattersA homogeneous pattern hints at DNA and chromatin antibodies, centromere at scleroderma, and speckled at several overlap conditions.
- DNA (DS) AntibodyTargets your own double-stranded DNA and is one of the most specific markers for lupus, used to confirm and follow the disease.Why it mattersRising levels often precede a lupus flare and track closely with kidney involvement.
- Anti-Sm AntibodyAntibodies against a nuclear protein called Smith; uncommon but highly specific for lupus, especially alongside anti-double-stranded DNA antibodies.Why it mattersA positive result strongly supports lupus and, paired with anti-DNA, signals higher disease activity.
- Scleroderma AntibodyAlso called anti-Scl-70; marks diffuse scleroderma and carries the strongest link to scarring lung disease and worse outcomes.Why it mattersA positive result raises the risk of diffuse skin disease and lung scarring, warranting lung monitoring.
- J-o1 AntibodyTargets an enzyme inside muscle cells; the defining marker of antisynthetase syndrome, which pairs muscle inflammation with interstitial lung disease.Why it mattersA positive Jo-1 points to antisynthetase syndrome and a high likelihood of associated lung scarring.
- SS-A AntibodyAlso called anti-Ro; a leading marker for Sjögren's disease that also appears in lupus and carries pregnancy-related heart considerations.Why it mattersA positive SS-A points to Sjögren's or a lupus overlap and, in pregnancy, carries a roughly 1-2% risk of fetal heart block.
- SS-B AntibodyAlso called anti-La; usually appears alongside SS-A and strengthens the case for Sjögren's disease over other conditions.Why it mattersSS-B rarely appears alone; together with SS-A it makes Sjögren's the more likely diagnosis.
- RNP AntibodyTargets a ribonucleoprotein complex; high levels are the defining marker of mixed connective tissue disease, which blends features of several conditions.Why it mattersHigh RNP with mixed lupus, scleroderma, and muscle features together points to mixed connective tissue disease.
- Chromatin AntibodyTargets the packaged bundle of DNA and proteins inside the nucleus, reinforcing a lupus diagnosis and helping flag kidney risk.Why it mattersPositive chromatin antibodies alongside anti-DNA point to a higher likelihood of lupus kidney disease.
- Centromere B AntibodyMarks the limited form of scleroderma and is the tightest pattern-to-antibody match in the panel, generally a milder lung course.Why it mattersPositive centromere antibodies favor limited scleroderma, which carries lower lung-scarring risk than the diffuse form.
About Comprehensive ANA Panel
A positive result on a basic autoimmune screen is one of the most common and most misread findings in lab medicine. On its own it says only that your immune system may be making antibodies against your own cells, not whether you are sick or with what.
This panel exists to answer the next question. It pairs the broad screen, called an antinuclear antibody or ANA test, with the specific antibodies tied to individual diseases, turning a vague positive into a targeted map of lupus, Sjögren's, scleroderma, and related conditions.
What This Panel Reveals
The panel works in two layers. The first is the screen itself, reported three ways: whether antibodies are present, how strong the signal is (the titer, meaning how far your blood can be diluted and still test positive), and the staining shape those antibodies make under a microscope (the pattern). Titer carries real weight. In one study of people with systemic autoimmune rheumatic disease, a titer of 1:320 or higher predicted true disease correctly 84.0% of the time, while only 12.2% of healthy people tested positive at all compared with 78.7% of those with disease.
The second layer names the culprit. A broad screen is sensitive but not specific, so the panel adds antibodies that lock a result to a particular disease. The lupus markers are the ones against your own genetic material (anti-double-stranded DNA), against a protein called Smith (anti-Sm), and against the DNA-protein bundle in the nucleus (anti-chromatin). The Sjögren's and overlap markers are SS-A and SS-B. The scleroderma markers are Scl-70 and centromere B. One marker (RNP) defines mixed connective tissue disease, and one (Jo-1) points to antisynthetase syndrome, a form of inflammatory muscle disease defined by muscle inflammation, lung scarring, arthritis, and Raynaud phenomenon.
This is why the combination beats any single test. Adding specific-antibody testing to the microscope screen raised the ability to catch true disease from 89.2% to 97.4%, and the ability to correctly rule it out from 64.6% to 98.4%, in a large multicenter study. The screen alone finds smoke; the specific antibodies find the fire.
How to Read Your Results Together
No single line on this report is a diagnosis. The meaning lives in the combinations. A few patterns cover most real-world results.
| Your Result Pattern | What It Points Toward |
|---|---|
| High-titer screen with anti-double-stranded DNA or anti-Sm | Systemic lupus, the classic lupus antibody profile |
| Positive screen with SS-A and SS-B | Sjögren's disease or a lupus overlap, especially with dry eyes and mouth |
| Positive screen with centromere B versus Scl-70 | Limited scleroderma (centromere, milder lungs) versus diffuse scleroderma (Scl-70, higher lung risk) |
| High-titer speckled screen with RNP or Jo-1 | Mixed connective tissue disease (RNP) or antisynthetase syndrome, an inflammatory muscle disease with lung involvement (Jo-1) |
The specific antibodies also carry prognostic weight, not just labels. In a study of 1,325 people with scleroderma, those with centromere antibodies and limited skin disease had the highest 20-year survival at 65.3% and the lowest rate of significant lung scarring at 8.5%. Those with Scl-70 antibodies had lung fibrosis rates of 86.1% and 84.0% at 15 years, and the diffuse-disease group had 20-year survival of 32.4%. In lupus, carrying both anti-double-stranded DNA and anti-Sm antibodies together signals higher disease activity than either alone.
What to Do with Your Results
If a specific antibody is positive and you have matching symptoms, such as joint pain, rashes, dry eyes, skin tightening, or muscle weakness, that combination is your cue to see a rheumatologist. A positive screen with no specific antibodies and no symptoms usually needs watchful waiting, not alarm. Companion tests sharpen the picture: inflammation markers and complement proteins track lupus activity, and a urine protein check screens for the kidney involvement that anti-double-stranded DNA and anti-chromatin antibodies flag.
Serial tracking matters most once a disease is known. Anti-double-stranded DNA antibodies tend to rise before a lupus flare and move with kidney involvement, so repeating them helps you see trouble coming. Many other antibodies, such as SS-A, SS-B, Sm, and RNP, stay fairly stable once positive, so they rarely need frequent rechecks. If you are actively managing a diagnosed condition, retesting the activity-linked markers gives your care team a trend to act on; when lupus kidney disease is active, current rheumatology guidance checks anti-double-stranded DNA at each clinic visit, while every 6 to 12 months is reasonable when disease is stable.
When Results Can Be Misleading
The whole panel shares one weakness: a low-level positive screen is common in healthy people. Roughly 10% to 12% of healthy adults are positive at a 1:80 dilution, about 5% at 1:160, and only 3% at 1:320, so low titers alone mean little. These percentages are approximate and vary with age, sex, population, and the lab method used. In one referral clinic, a positive screen predicted lupus only 2.1% of the time and any autoimmune rheumatic disease only 9.1% of the time, and no disease at all was found in people below a 1:160 titer.
Two other factors distort the entire panel at once. Different labs use different methods and cutoffs, so the same blood can read differently from one lab to the next; tracking trends within a single lab is more reliable than comparing across them. And a specific harmless pattern (called dense fine speckled) argues against serious autoimmune disease even when the screen is positive. Read together with your symptoms, though, the specific antibodies cut through most of this noise.